▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #678 by analyst upside · 2026-09-28
MOLN
Molecular Partners AG
Healthcare · Market Cap $165M · P/E 0x
ANALYST PRICE TARGET
+142.0%
implied upside to consensus target
Current Price $4.3
Consensus Target $10.4
Bull Target $16.44
Bear Target $3.65
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
1
Sell
0
52-Week Low $3.53
52-Week High $5.36
YTD Return +1.9%
FUNDAMENTALS
Market Cap $165M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.63
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.53
52-Week High $5.36
Current Price $4.3
Bear Target $3.65
Bull Target $16.44
● Now $4.3 ● Target $10.4
TRADING DATA
Avg Volume 3K
YTD Return +1.9%
Analyst Count 5
Consensus Buy
Upside to Target +142.0%
Last Updated 2026-09-28

ANALYST SUMMARY

Molecular Partners AG (MOLN) is currently trading at $4.3 with a Wall Street consensus price target of $10.4, implying potential upside of 142.0% over the next 12 months. 5 analysts currently cover MOLN, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $16.44, while the most cautious has a target of $3.65.

MOLN operates in the Healthcare sector with a market capitalisation of $165M. The stock is up 1.9% year-to-date and is currently trading near the lower end of its 52-week range of $3.53 – $5.36.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MOLN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-04-22 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-16 31% win rate (48 calls)
HC Wainwright & Co. ● Initiated
Buy 2026-01-27 31% win rate (48 calls)
JP Morgan - Reiterated
Neutral → Neutral 2025-12-08 43% win rate (7 calls)
JP Morgan - Reiterated
Neutral → Neutral 2025-09-03 43% win rate (7 calls)
LifeSci Capital ● Initiated
Outperform 2025-03-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
36
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →